Yomo S, et al. - Herein, stereotactic radiosurgery (SRS) was assessed for efficacy as well as limitations as a treatment option for brain metastases (BM) from EGFR-mutant lung adenocarcinoma, when administered with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI). As a treatment option for EGFR-mutant lung adenocarcinoma patients with limited BM, the upfront SRS strategy was shown to be minimally invasive and effective. Furthermore, EGFR-TKI naïve patients were found to be a distinct subgroup for which a longer survival time and durable intracranial disease control could be expected.